Therapy Detail

Therapy Name YW3-56
Therapy Description

YW3-56 is a peptidylarginine deiminase (PAD) inhibitor with activity against PAD2 and PAD4, which results in decreased histone citrullination and activation of the endoplasmic reticulum stress response, potentially resulting in decreased tumor cell growth (PMID: 22605338, PMID: 25612620).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
YW3-56 YW3-56 is a peptidylarginine deiminase (PAD) inhibitor with activity against PAD2 and PAD4, which results in decreased histone citrullination and activation of the endoplasmic reticulum stress response, potentially resulting in decreased tumor cell growth (PMID: 22605338, PMID: 25612620).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown colorectal cancer not applicable YW3-56 Preclinical Actionable In a preclinical study, YW3-56 inhibited proliferation of colorectal cancer cell lines in culture, independent of TP53 status (PMID: 25612620). 25612620
Unknown unknown lung carcinoma not applicable YW3-56 Preclinical Actionable In a preclinical study, YW3-56 inhibited proliferation of lung carcinoma cell lines in culture, independent of TP53 status (PMID: 25612620). 25612620
Unknown unknown osteosarcoma not applicable YW3-56 Preclinical Actionable In a preclinical study, YW3-56 inhibited proliferation of a human osteosarcoma cell line in culture (PMID: 25612620). 25612620
TP53 R280K triple-receptor negative breast cancer sensitive YW3-56 Preclinical - Cell line xenograft Actionable In a preclinical study, YW3-56 inhibited proliferation of a human triple-negative breast cancer (TNBC) cell line harboring TP53 R280K in culture and inhibited tumor growth in TP53 R280K-mutant TNBC cell line xenograft models (PMID: 25612620). 25612620
Unknown unknown hepatocellular carcinoma not applicable YW3-56 Preclinical Actionable In a preclinical study, YW3-56 inhibited proliferation of a human hepatocellular carcinoma cell line in culture (PMID: 25612620). 25612620
Unknown unknown leukemia not applicable YW3-56 Preclinical Actionable In a preclinical study, YW3-56 inhibited proliferation of human leukemia cell lines in culture, independent of TP53 mutational status (PMID: 25612620). 25612620
Unknown unknown Advanced Solid Tumor not applicable YW3-56 Preclinical Actionable In a preclinical study, YW3-56 inhibited proliferation of a variety of human tumor cell lines in culture, independent of TP53 mutational status (PMID: 25612620). 25612620
Clinical Trial Phase Therapies Title Recruitment Status